Doxorubicin or Adriamycin, is one of the most widely used chemotherapeutic drug for
treating a myriad of cancers. It induces cell death through multiple intracellular targets …

Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

The production of reactive species is a core of the redox cycling profile of anthracyclines.
However, these molecular characteristics can be viewed as a double‐edged sword acting …

Through the success of basic and disease-specific research, cancer survivors are one of the
largest growing subsets of individuals accessing the healthcare system. Interestingly …

Despite significant therapeutic advances, the prognosis of patients with heart failure (HF)
remains poor, and current therapeutic approaches are palliative in the sense that they do not …

Doxorubicin (DOX) is an anticancer anthracycline that presents a dose‐dependent and
cumulative cardiotoxicity as one of the most serious side effects. Several hypotheses have …

Cell death and injury often lead to release or exposure of intracellular molecules called
damage-associated molecular patterns (DAMPs) or cell death-associated molecules. These …

Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion
of cancer therapies and the short-and long-term quality of life. Anthracyclines are currently …

The spectrum of cardiac side-effects of cancer chemotherapy has expanded with the
development of combination, adjuvant and targeted chemotherapies. Their administration in …

The patient is a 63-year-old man with a history of wellcontrolled hypertension who is
diagnosed with diffuse large B-cell lymphoma and treated with a doxorubicincontaining …